This review outlines the progress in our understanding of the epitopes and specificity of mouse mAbs, human mAbs and polyclonal sera against DENV surface proteins, the envelope (E) and precursor membrane (prM) proteins, following natural infection; and their implication for new strategies of dengue vaccine to induce more potent neutralizing Abs and less enhancing Abs. This evidence concerns the gene DDX41 and infection.